andrewkaretas, Author at Allogene

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Post author:andrewkaretas
Post published:April 26, 2024
Post category:Latest News

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential…

EFFECT: EFFECT

Post author:andrewkaretas
Post published:April 26, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:April 24, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

ARS: An annual report to security holders

Post author:andrewkaretas
Post published:April 23, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

DEFA14A: Additional proxy soliciting materials – definitive

Post author:andrewkaretas
Post published:April 23, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

DEF 14A: Official notification to shareholders of matters to be brought to a vote (“Proxy”)

Post author:andrewkaretas
Post published:April 23, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

Post author:andrewkaretas
Post published:April 22, 2024
Post category:SEC Filings

Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Q2 Investor Conference Participation

Post author:andrewkaretas
Post published:April 9, 2024
Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…